Bio-Rad launches Vericheck ddPCR replication competent AAV and lentivirus kits for cell and gene therapy production

Published: 28-Feb-2024

The kits allow for the quantification of replication competent lentivirus and adeno-associated viruses

Bio-Rad Laboratories, a global company specialising in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCR replication competent lentivirus kit and the Vericheck ddPCR replication competent AAV kit.

The kits provide rapid, cost-effective solutions for the absolute quantification of replication competent lentivirus (RCL) and replication competent adeno-associated virus (RCAAV), supporting the safe and effective production of cell and gene therapies. 

Replication competent viruses (RCVs) can infect cells and replicate to produce additional virions. 

They can be generated through recombination events between the transfer plasmid and either the production plasmids or the packaging cell line's genome.

Fundamental to the safety of emerging cell and gene therapies, RCV testing of samples must be performed throughout the production process. 

Bio-Rad’s Vericheck ddPCR kits for detection of RCL and RCAAV provide a solution for highly specific and highly sensitive detection and quantification of viral replication genes, potentially indicating an RCV. 

The tests are designed for Bio-Rad's QX Droplet Digital PCR (ddPCR) platforms, with a simple workflow including automated data analysis and flexible sample throughput. 

The kits allow for rapid turnaround, with results being available in 8 hours.

“As the number of cell and gene therapies entering the market increases, we see a growing emphasis on the need for products to ensure safety and efficacy across production processes. We believe that Droplet Digital PCR solutions can help address this unmet need,” said Carolyn Reifsnyder, Senior Director of Marketing at Bio-Rad.




You may also like